Disclosures: Wei Zhang: Nothing to Disclose, Ana Ivkovic: Nothing to Disclose, Kimberly Schoener: Nothing to Disclose, Kelly Hsu: Nothing to Disclose, Sienna Li: Nothing to Disclose, Samantha Nunes: Nothing to Disclose, KIMBERLY SULLIVAN: Nothing to Disclose, Emily Bethea: Nothing to Disclose, Heidi Yeh: Nothing to Disclose 1313 INCIDENCE AND OUTCOME OF REJECTION IN HYPERIMMUNIZED LIVER TRANSPLANT RECIPIENTS RECEIVING AN INDUCTION THERAPY Faouzi Saliba 1 Nada El-Domiaty 2 lea Duhaut 1 Audrey Coilly 1 Eleonora De Martin 1 Sophie-Caroline Sacleux 1 Wafaa Ibrahim 3 Philippe Ichai 1 Gabriella Pittau 1 Oriana Ciacio 1 Chady Salloum 1 Daniel Azoulay 1 Eric Vibert 1 Ren Adam 1 Jean Luc Taupin 4 Mylene Sebagh 1 Daniel Cherqui 1 Didier Samuel 1 , 1 AP-HP Hpital Paul Brousse, 2 Hpital Paul Brousse& Helwan university, 3 Cairo University, 4 Groupe Hospitalier St-Louis Lariboisire Background: Liver transplantation (LT) for hyperimmunized recipients with positive crossmatch or with preformed Donor specific antibodies (pDSA) present a unique challenge due to increased risk of antibody-mediated rejection (ABMR) and graft failure
Zinkernagel AS, Timmer AM, Pence MA, Locke JB, Buchanan JT, Turner CE, Mishalian I, Sriskandan S, Hanski E, Nizet V (2008) The IL-8 protease SpyCEP/ScpC of group A Streptococcus promotes resistance to neutrophil killing
J Learn Disabil (1982) 15:3336
Inflammation 45 (6), 23392351
